Abbott Laboratories (ABT) Tops Q1 EPS by 5c; Reaffirms FY14 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq hit record highs as Treasury yields stall, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $98.39 -1.71%
Revenue Growth %: +14.2%
Financial Fact:
Selling, general and administrative: 1.63B
Today's EPS Names:
TMQ, OMH, AEHR, More
Revenue Growth %: +14.2%
Financial Fact:
Selling, general and administrative: 1.63B
Today's EPS Names:
TMQ, OMH, AEHR, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q1 ongoing EPS of $0.41, $0.05 better than the analyst estimate of $0.36. Revenue for the quarter came in at $5.24 billion versus the consensus estimate of $5.29 billion.
Abbott reaffirmed FY2014 guidance.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Highlights Two Machinery Names To Own
- Circle Internet Group (CRCL) PT Raised to $115 at US Tiger Securities
- Fortrea shares jump after Barclays upgrade to Overweight
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
